I n most cases of chronic myeloid leukaemia (CML), a daily oral medication can rapidly transform a progressive and ultimately fatal cancer into a chronic but manageable condition. But this is not a cure. The persistence of quiescent (dormant, non-cycling) and thus drug-resistant leukaemic stem cells (LSCs) poses an unmet clinical challenge, and any attempt to cure CML must target the eradication of these cells. In this issue, Prost et al. 1 (page 380) present provocative preclinical and early clinical findings demonstrating that a drug currently used for diabetes therapy can be repositioned to target a pathway that controls quiescence in LSCs, causing the gradual erosion of this cellular pool.
The cause of CML is a mutation in a normal blood stem cell involving an exchange of genetic material between chromosomes 9 and 22. This translocation creates a cancerdriving gene known as BCR-ABL1, which produces a protein with enhanced activity as a tyrosine kinase enzyme, leading to un controlled cell proliferation. BCR-ABL1 has been shown to be sufficient to drive the development of leukaemia in mouse models 2 , and the discovery of this protein led to the development of tyrosine kinase inhibitors (TKIs) for CML treatment.
In the past two decades, TKIs have dramatically improved the outcome for people with this cancer. Most of those who present with early disease respond rapidly to TKI therapy and go into long-lasting remission. However, TKIs fail to eradicate LSCs, the cells that initiate and maintain CML, and these drugresistant cells can drive relapse, or evolve to cause further forms of TKI resistance and more-aggressive disease. As a result, people on life-long TKI therapy are exposed to associated, often serious, side effects and may cease to respond to the treatment at any time. Furthermore, the significantly improved survival for those taking TKIs means that the prevalence of CML is increasing each year, with inherent social and economic implications.
Several potential mechanisms to explain the insensitivity of LSCs to TKIs have been proposed, including cellular quiescence. Prost et al. report that quiescence in LSCs is regulated by a pathway involving the receptor PPARγ, the transcription factors STAT5 and HIF2α, and the protein CITED2, which is known 3 to regulate blood stem-cell quiescence (Fig. 1) . A particular strength of the study was the use of primary blood stem cells (expressing the marker CD34) from people with CML to dissect the pathway and confirm the role of each component in regulating LSC quiescence.
The authors go on to show that combining imatinib, the standard TKI used to manage CML, with the antidiabetic agent pioglitazone, which activates PPARγ, blocks this pathway in CML cells. The synergistic effects of the drugs reduce STAT5 expression and activity, downregulate HIF2α and CITED2 expression, and trigger the death of quiescent LSCs. Although the mechanism by which LSCs are killed in response to this drug combination is not clear, they are probably either killed directly or driven to exit quiescence, which may lead to their eradication by the TKI. The authors also demonstrate that the compound JQ1, a bromodomain inhibitor with broad activity that includes the suppression of STAT5 activity, is as effective as pioglitazone (in combination with imatinib). Although this finding supports a role for the STAT5 pathway in LSC quiescence, the door is still open for studies of other agents that may target LSCs through this or alternative pathways.
Collectively, these results strengthen the concept that cancer stem cells exhibit vulnerabilities in otherwise normal molecular pathways that may be targeted in a selective manner to obtain a cure. Earlier work demonstrated that CML stem-cell quiescence is in part maintained by the promyelocytic leukaemia tumour-suppressor protein, which can be targeted by arsenic trioxide 4 , and that the cellular process of autophagy functions as a survival pathway for CML stem cells that can be targeted by repositioning the antimalarial agent hydroxychloroquine 5 ( Fig. 1 ). Both of these approaches are currently under investigation in the clinic.
Prost et al. also tested the addition of pio glitazone to imatinib therapy in three people with CML, and found that they converted from having demonstrable residual leukaemia to being disease-free. The effect lasted for months to years after pioglitazone treatment 1 describe a molecular pathway, involving the receptor PPARγ, the transcription factors STAT5 and HIF2α, and the regulatory protein CITED2, that induces leukaemic stem cells (LSCs) to enter a dormant (quiescent) state. They also show that the drug pioglitazone, approved for diabetes treatment, activates PPARγ to block this pathway, and can kill these cells when used in conjunction with tyrosine kinase inhibitors (TKIs), which inhibit the protein BCR-ABL1 and thus STAT5, and which are the standard therapy against active (cycling) leukaemic cells. Several drugs used to treat other diseases, such as axitinib, arsenic trioxide and hydroxychloroquine, have also been repositioned to treat chronic myeloid leukaemia, but these have different mechanisms of action.
E R I C A W. C A R L S O N
T he quantum motion of electrons enforces a high degree of homogeneity in conventional materials such as metals and semiconductors. As a result, the electrons spread out evenly in these materials, like liquid filling a container. By contrast, nanoscale images of copper oxide (cuprate) superconductors have revealed that the mater ials' electrons form clumps at the surface 1 . On page 359 of this issue, Campi et al. 2 report X-ray images of a cuprate superconductor, revealing complex patterns of electrons 3 that are also scaffolded throughout the interior of the material, and on a much larger scale than has been observed before. Just like the skeleton of a coral reef, where, the greater the scale on which the reef is observed, the more complexity meets the eye, the electrons in these materials form structures full of gnarled hollows of varying size.
Campi and colleagues find that the size of the patterns formed by electrons is strongly tied to the degree to which the cuprate superconductor is doped -meaning that a small amount of one type of atom is substituted for another, to change the charge available for conducting current through the material. Materials that have a uniform distribution of electrons, such as semiconductors, are typically robust against spatial variations in doping level. Nanostructures are a notable exception: variations in doping level affect the performance of the smallest semi conductor devices. The electrons inside cuprate compounds that superconduct at high temperatures (up to 160 kelvin) spontaneously form nano structures, and so these materials are sensitive to local doping variations.
The authors made their discovery using a technique called scanning micro X-ray diffraction. In this approach, as highenergy light moves through a material, it bends at an angle that depends on the periodicity of local charge variations in the mater ial. It was already known that the charge in cuprate superconductors is often locally ordered into a uni directional pattern, with a periodicity of about four crystalline unit cells (the smallest periodically repeating structures in a crystal), so that the electron-density distribution resembles striped wallpaper 1, 4, 5 . Campi et al. scan a micrometre-sized X-ray beam across a superconducting sample to probe how the character of this stripy chargedensity wave varies from spot to spot in the material. But instead of a single sheet of 'striped wallpaper' , they find rips, tears and patches in the electronic texture, as though someone had papered a wall with sheets of many different sizes and shapes, and with complete dis regard for whether the borders matched up.
As in nanostructure semi conductors, these electronic textures in cuprate superconductors are sensitive to local variations in the doping level on nanometre and micrometre scales. For example, the lower the level of local oxygen doping, the higher is the contrast of the charge-density waves (bright wallpaper stripes), introducing greater disorder into the overall charge pattern.
These effects are important for superconductivity because of two factors: dimensionality and connectivity. The behaviour of electrons ultimately depends on the shape of their quantum-mechanical waves, and waves show vastly different behaviour in different dimensions. In three dimensions, the energy carried by a wave over a distance r spreads out as r −2 , as in sound waves coming from a speaker. In two dimensions, such as in ripples emanating from a pebble thrown into a pond, the distance dependence changes to r −1 . In one dimension, waves cannot dissipate by spreading out. Like the bow waves of canal tugboats, there is only one way for a wave to go in one dimension: forward. The charge-density structures that Campi et al. find are enticing, because they effectively reduce the dimensionality that electrons can explore, which can lead to mechanisms of superconductivity that are fundamentally different from those of conventional superconductors 6, 7 . However, the dimensionality that Campi et al. infer is not integer. They find that the sizes of the patches formed by the chargedensity waves are distributed according to a power law, which is typical of fractal dimensions. Like any good fractal, these patterns display similarities whether they are observed from close up or far away. Although much ceased. These data provided a strong rationale for a phase II clinical trial, which started in July 2009 (ACTIM EudraCT 2009-011675-79). Although the interim results from this trial are encouraging, the study is non-randomized, so it will be difficult to ascertain definitively that improved response rates are driven by pioglitazone.
Despite the need for further clinical testing of this combination therapy, Prost et al. have demonstrated the substantial potential for drug repositioning in CML research. Their results follow a recent report 6 in which axitinib, a TKI approved for the treatment of drugresistant renal-cell cancer, was repositioned to tackle TKI resistance in CML. Using drugs that have already been approved for other purposes can shorten the drug-development pathway by 5-10 years and reduce risks and costs.
Although drug repositioning can be rather serendipitous, Prost and colleagues had a tangible rationale that PPARγ activators such as pioglitazone warranted investigation in CML on the basis of their observation 7 of the drugs' activity against a cell-line model of the disease. Already around 30% of drugs newly approved for a particular treatment have been repositioned from another therapy, and such hypothesis-driven repositioning strategies are likely to become more common in cancer drug discovery. This figure is set to rise further as our understanding of cellular pathways and processes increases and we include innovative computational approaches to facilitate disease-, drug-and treatment-oriented drug repositioning. It is clear that repositioning will increasingly help the fast-tracking of drugs into the clinic. As demonstrated by 
